Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a two-cohort, phase II study

por Hensley, Martee L., Kravetz, Sara, Jia, Xiaoyu, Iasonos, Alexia, Tew, William, Pereira, Lauren, Sabbatini, Paul, Whalen, Christin, Aghajanian, Carol A., Zarwan, Corinne, Berlin, Suzanne
Publicado 2011

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

por O’Cearbhaill, Roisin E., Ragupathi, Govind, Zhu, Jianglong, Wan, Qian, Mironov, Svetlana, Yang, Guangbin, Spassova, Maria K., Iasonos, Alexia, Kravetz, Sara, Ouerfelli, Ouathek, Spriggs, David R., Danishefsky, Samuel J., Sabbatini, Paul J.
Publicado en Cancers (Basel) (2016)

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, Intravenous/Intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer

por Cadoo, Karen A., Grisham, Rachel N., O’Cearbhaill, Roisin E., Boucicaut, Nicole N., Henson, Melissa, Iasonos, Alexia, Zhou, Qin, Sarasohn, Debra M., Gallagher, Jacqueline, Kravetz, Sara, Zamarin, Dmitriy, Makker, Vicky, Sabbatini, Paul J., Tew, William P., Aghajanian, Carol, Konner, Jason A.
Publicado en Gynecol Oncol (2020)